Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2017—Asuragen entered into a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of capillary electrophoresis-based in vitro diagnostics. Asuragen will leverage its AmplideX PCR/CE product technologies to develop diagnostic kits for the 3500 Dx Series Genetic Analyzer CS2 instrument.
May 2017—Nova Biomedical received the CE mark for its Allegro, a capillary blood analyzer for point-of-care testing in primary care settings. Allegro and its StatStrip A companion meter provide 14 clinically important tests to monitor glycemic control, assess cardiac risk with a full lipids panel, and assess kidney function. Results are ready during the patient visit.
April 2017—Proscia, a data solutions provider for digital pathology founded in 2014 by a team from Johns Hopkins, the Moffitt Cancer Center, and the University of Pittsburgh, and Asan Medical Center, a South Korean clinical and biomedical research institute, announced a partnership focused on developing tools that enable predictive medicine in the fight against cancer.
April 2017—ViroStat has introduced three Monotope monoclonal antibodies that are specific to Chlamydia pneumonia and do not cross-react with the related Chlamydia trachomatis and Chlamydia psittaci. They function in ELISA and IFA and are candidates for rapid test applications.
April 2017—Bio SB announced it now offers 25 monoclonal antibodies for IVD applications. Among the new products is a line of reagents for mesothelioma diagnosis, including BAP1, mesothelial cell HBME 1, and caveolin 1.
April 2017—The Diesse Mini-Cube automated sed-rate instrument is now compatible with 500 µL patient samples in BD Microtainer tubes with K2 EDTA. The Mini-Cube also analyzes standard 13 × 75 mm K2 EDTA tubes with a patient sample fill volume range of 2.0 mL to 4.0 mL.
April 2017—Quest Diagnostics launched a test service that aims to help physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus. The HBsAg qualitative test is used to aid in diagnosis of patients with HBV.
April 2017—The new IsoFreeze PCR Rack from Sarstedt aims to ensure consistently cooled PCR samples. Premature warming of PCR samples during preparation can result in nonspecific PCR products.
April 2017—SeraCare Life Sciences launched its Seraseq Fusion RNA Mix v2 and Seraseq FFPE Fusion RNA Reference Material v2. The highly multiplexed mixes include 15 clinically actionable fusion RNA partners. Two formats are offered—purified nucleic acid (Fusion RNA Mix) and formalin-fixed, paraffin-embedded tissue slices (FFPE Fusion RNA Reference material).
April 2017—MedTest announced the commercial launch of urine drugs of abuse screening reagents on the Mindray BA-800M chemistry analyzer for use in clinical laboratories in the United States.
